Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia : results of the first randomized phase III trial

Autor: Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Susan O'Brien, Paolo Ghia, Peter Hillmen, Kara Higgins, Richard R. Furman, Tadeusz Robak, Wojciech Jurczak, José A. García-Marco, Arnon P. Kater, Priti Patel, Stephan Stilgenbauer, Mustafa Nuri Yenerel, John C. Byrd, Asher Chanan-Khan, Neil E. Kay, Javier Pinilla-Ibarz, Árpád Illés, Anthony R. Mato, John F. Seymour, Sophia Sohoni, Stéphane Leprêtre

Publikováno v: Journal of clinical oncology, 39(31), 3441-3452. American Society of Clinical Oncology
J Clin Oncol

PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f6a2d584eece7d575bd2a5951f783fb
https://ruj.uj.edu.pl/xmlui/handle/item/290438

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Autor: Hope Qamoos, Catherine Thieblemont, Wojciech Jurczak, Wayne Rothbaum, Peter Hillmen, John C. Byrd, Anne Uyei

Publikováno v: Blood. 136:23-24

Background: Insights into molecular biology and signaling pathways have led to the development of innovative therapeutic strategies to treat B-cell malignacies. In R/R CLL, targeted agents including Bruton tyrosine kinase inhibitors (BTKi) and B-cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4352d703d9d8cc0d4da5ffbd138f448b
https://doi.org/10.1182/blood-2020-134901

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Autor: Priti Patel, Raquel Izumi, Richa Dua, Eric D. Jacobsen, Ahmed Hamdy, Stephen D. Smith, Pier Luigi Zinzani, Jeanette K. Doorduijn, Lucie Oberic, Andrew Davies, Andre Goy, Arnon P. Kater, Wayne Rothbaum, Carlos Panizo, Taduesz Robak, Franck Morschhauser, Thierry Lamy, Simon Rule, Todd Covey, Richard Eek, Steven Le Gouill, Jehan Dupuis, J. Greg Slatter, Michael Wang, Xin Huang, Gandhi Damaj, Olivier Casasnovas, Bijal D. Shah, Wojciech Jurczak

Publikováno v: Lancet (UK), 391(10121), 659-667. Elsevier Ltd.
Lancet
Lancet, Elsevier, 2018, 391 (10121), pp.659-667. ⟨10.1016/S0140-6736(17)33108-2⟩
The Lancet
The Lancet, Elsevier, 2018, 391 (10121), pp.659-667. 〈http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33108-2/fulltext〉. 〈10.1016/S0140-6736(17)33108-2〉
Lancet, 391(10121), 659-667. Elsevier Limited
The Lancet, Elsevier, 2018, 391 (10121), pp.659-667. ⟨10.1016/S0140-6736(17)33108-2⟩
The Lancet, 2018, 391 (10121), pp.659-667. ⟨10.1016/S0140-6736(17)33108-2⟩
The Lancet, 391(10121), 659-667. Elsevier Limited

International audience; BACKGROUND:Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.METHO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40338a16268a02f399b76db7fd8f2550
http://hdl.handle.net/11585/615095

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Autor: Srdan Verstovsek, László Rejtő, Joanne Ewing, Eric Jourdan, Marek Hus, Jesse McGreivy, Philipp J. Jost, Wayne Rothbaum, Sebastian Grosicki, Holger Hebart, Regina Garcia-Delgado, Andrzej Pluta, Donal P. McLornan, Haifa Kathrin Al-Ali, Irum Khan

Publikováno v: Blood. 134:2945-2945

Background: Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by progressive bone marrow fibrosis, ineffective erythropoiesis, dysplastic megakaryocyte hyperplasia, and extramedullary hematopoiesis. MF includes primary MF (PMF),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ccf82a3fce9a6d30d659d3dc45146910
https://doi.org/10.1182/blood-2019-123836

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

Autor: Bridget K. Urie, Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Kevin R. Coombes, Bonnie K. Harrington, Xiaoli Zhang, William C. Kisseberth, Amy J. Johnson, John C. Byrd, Cecile M. Krejsa, Christopher C. Coss, Duncan S. Russell, Heather L. Gardner, Cheryl A. London, Bart Van Lith, Todd Covey, Allard Kaptein, Michael Gulrajani

Publikováno v: PLoS ONE, Vol 11, Iss 7, p e0159607 (2016)
PLoS ONE

Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring cani

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f327087ab44b2252ce16d4aa8b2fad95
http://europepmc.org/articles/PMC4951150?pdf=render